FLT3-targeted therapy restores GATA1 pathway function in NPM1/FLT3-ITD mutated acute myeloid leukaemia.
FLT3 inhibitors
FLT3‐ITD
GATA1
acute myeloid leukaemia
heamatological malignancies
leukaemia therapy
Journal
EJHaem
ISSN: 2688-6146
Titre abrégé: EJHaem
Pays: United States
ID NLM: 101761942
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
19
05
2023
revised:
05
06
2023
accepted:
09
06
2023
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
One-third of newly diagnosed adult acute myeloid leukaemia (AML) carry
Identifiants
pubmed: 38024637
doi: 10.1002/jha2.738
pii: JHA2738
pmc: PMC10660397
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1100-1104Subventions
Organisme : European Research Council
ID : 740230
Pays : International
Informations de copyright
© 2023 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
B. Falini applied for a patent on the clinical use of NPM1 mutants. The other authors declare no conflict of interest.
Références
Mol Cell Biol. 2005 Feb;25(4):1215-27
pubmed: 15684376
Eur J Haematol. 2017 Apr;98(4):330-336
pubmed: 28000291
Leukemia. 1996 Dec;10(12):1911-8
pubmed: 8946930
N Engl J Med. 2013 May 30;368(22):2059-74
pubmed: 23634996
Blood. 2021 Feb 4;137(5):589-599
pubmed: 33171486
Leuk Lymphoma. 2005 Dec;46(12):1679-87
pubmed: 16263569
Leukemia. 2019 Jul;33(7):1827-1832
pubmed: 30755706
Transplant Cell Ther. 2021 Feb;27(2):153-162
pubmed: 33017662
Blood. 2020 Aug 6;136(6):698-714
pubmed: 32350520
Blood. 2013 Apr 25;121(17):3447-58
pubmed: 23435463
Blood. 2020 Oct 8;136(15):1707-1721
pubmed: 32609823
Clin Cancer Res. 2014 May 1;20(9):2363-74
pubmed: 24619500
Cancer Cell Int. 2012 Jun 07;12(1):25
pubmed: 22676581
N Engl J Med. 2005 Jan 20;352(3):254-66
pubmed: 15659725